NightHawk Biosciences, Inc. (NHWK) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NightHawk Biosciences, Inc. (NHWK) Healthcare & Pipeline Overview

NightHawk Biosciences, Inc. is a biopharmaceutical firm specializing in immune therapies and vaccines for cancer and infectious diseases. Utilizing its proprietary gp96 platform, the company develops novel product candidates, including HS-110 for non-small cell lung cancer and HS-130 for advanced solid tumors, positioning itself within the evolving immuno-oncology landscape.

What Is the Investment Thesis for NHWK?

NightHawk Biosciences, Inc. presents an investment thesis centered on its proprietary gp96 platform and a developing clinical pipeline in immuno-oncology and infectious diseases. The company's core strength lies in its ImPACT and ComPACT technologies, which aim to harness the immune system against challenging diseases. Key value drivers include the progression of HS-110, which has completed Phase II enrollment for advanced non-small cell lung cancer, and the ongoing Phase I trials for HS-130 in solid tumors and PTX-35, a novel T-cell co-stimulator. Successful advancement through these clinical stages could unlock significant market potential in the multi-billion dollar oncology sector. The company's preclinical COVID-19 vaccine program also represents a potential future growth avenue. However, the investment carries inherent risks associated with biopharmaceutical development, including high attrition rates in clinical trials, the need for substantial future funding, and intense competition within the biotechnology industry. Investors should monitor clinical trial outcomes and the company's ability to secure strategic partnerships or additional capital to fund its extensive R&D efforts.

Based on FMP financials and quantitative analysis

NHWK Key Highlights

Market capitalization stands at $0.01 billion, reflecting its status as a small-cap biotechnology firm.

• The company reported a negative profit margin of -668.9%, indicative of significant R&D expenditures typical for a clinical-stage biopharmaceutical company.
• Gross margin is 9.8%, which is expected for a company primarily focused on research and development rather than commercial product sales.
• A Beta of 0.18 suggests lower volatility relative to the broader market, although this can be influenced by low trading volume for smaller companies.
• NightHawk Biosciences, Inc. does not currently pay a dividend, consistent with its growth-oriented stage of development and need to reinvest capital into its pipeline.

Who Are NHWK's Competitors?

NHWK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NHWK's Key Strengths?

Proprietary gp96 platform (ImPACT and ComPACT) offers unique immune modulation technologies.

• Advanced clinical pipeline with HS-110 in Phase II for NSCLC, demonstrating progress.
• Diversified pipeline targeting both oncology (solid tumors) and infectious diseases (COVID-19 vaccine).
• Collaboration with Dr. James Shapiro at the University of Alberta for PTX-35 manufacturing.

What Are NHWK's Weaknesses?

Significant negative profit margin (-668.9%) indicates high R&D costs and lack of commercial revenue.

• Early-stage nature of much of the pipeline (Phase I and preclinical) implies long development timelines and high risk.
• Small market capitalization ($0.01B) and relatively small employee base (77 employees) compared to larger biopharma competitors.
• Reliance on successful clinical trial outcomes for future viability and commercial success.

What Could Drive NHWK Stock Higher?

NHWK catalyst: Public release of top-line data from the completed Phase II clinical trial for HS-110 in advanced non-small cell lung cancer, which could provide significant validation for the gp96 platform.

• Announcement of initial safety and efficacy data from the ongoing Phase I clinical trials for HS-130 in advanced solid tumors, potentially de-risking the asset and supporting further development.
• Release of preliminary data from the ongoing Phase I development of PTX-35, a novel T-cell co-stimulator agonist antibody, which could demonstrate its potential in broad immunotherapy applications.
• Continued preclinical progress and potential IND filing for the COVID-19 vaccine candidate, signaling advancement towards human clinical trials and expanding the company's infectious disease pipeline.
• Formation of new strategic collaborations or licensing agreements for the gp96 platform or specific pipeline assets, which could provide non-dilutive funding and accelerate development.

What Are the Key Risks for NHWK?

Financial-distress signal — its Altman Z-Score of -0.72 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for pipeline candidates such as HS-110, HS-130, or PTX-35, which could significantly delay or halt development and impact investor confidence.
• The inherent challenges and high attrition rates associated with drug development, particularly in early-stage clinical trials, where the majority of candidates do not reach commercialization.
• Inability to secure sufficient future funding or strategic partnerships to support the extensive and costly research and development required for its clinical pipeline.
• Intense competitive pressure from larger pharmaceutical companies and other biotechnology firms developing similar or more advanced immune therapies and vaccines.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities for its drug candidates, which could prolong time-to-market and increase development costs.

What Are the Growth Opportunities for NHWK?

• Growth opportunity 1: Advancement of HS-110 in Non-Small Cell Lung Cancer (NSCLC). HS-110 has completed enrollment for its Phase II clinical trial, targeting advanced non-small cell lung cancer. The global NSCLC market is a multi-billion dollar opportunity, driven by high incidence rates and the need for improved treatment options, especially for advanced stages. Successful progression through Phase II and subsequent pivotal trials could position HS-110 as a significant therapeutic option, potentially leading to market entry within the next 3-5 years, subject to regulatory approvals. The unique mechanism of action through the gp96 platform could offer a differentiated profile in a competitive market.
• Growth opportunity 2: Development of HS-130 for Advanced Solid Tumors. HS-130 is currently undergoing a Phase I clinical trial for advanced solid tumors. The market for solid tumor treatments is vast and diverse, representing one of the largest segments in oncology. Positive data from early-stage trials could validate the therapeutic potential of HS-130 and support its advancement into later-stage clinical development. This asset could address unmet needs across various tumor types, potentially expanding NightHawk's market reach significantly over a 5-7 year timeline as it progresses through the rigorous clinical development pathway.
• Growth opportunity 3: Progression of PTX-35 and DR3/TNFRSF25 Targeting. PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25, is in Phase I development. The company is also exploring DR3/TNFRSF25 as a general target for various immunotherapy applications. This target represents a promising avenue for enhancing T-cell responses in cancer and potentially other immune-related diseases. The broader application of DR3/TNFRSF25 targeting could open up multiple therapeutic indications, creating a diversified pipeline beyond current candidates. The market for T-cell co-stimulators is growing, and successful development could lead to licensing opportunities or new product launches within 5-8 years.
• Growth opportunity 4: Development of a COVID-19 Vaccine. NightHawk Biosciences has a COVID-19 vaccine candidate in preclinical stages. While the initial wave of COVID-19 vaccines has been deployed, there remains an ongoing global need for updated, more effective, or broadly protective vaccines, especially against emerging variants or for specific populations. The global vaccine market is substantial, and a successful entry into this space could provide a significant revenue stream. Advancing this candidate through clinical trials could take 3-6 years, offering a long-term growth opportunity in the infectious disease segment.
• Growth opportunity 5: Leveraging the Proprietary gp96 Platform for New Indications and Partnerships. The gp96 platform, encompassing ImPACT and ComPACT technologies, is a foundational asset for NightHawk. Its ability to activate and expand T-cells and combine antigen-specific activation with targeted co-stimulation provides a versatile framework for developing new therapies. This platform could be leveraged to pursue additional indications beyond current pipeline assets, such as autoimmune diseases or other infectious diseases. Furthermore, the platform's unique capabilities could attract strategic partnerships or licensing agreements with larger pharmaceutical companies, providing non-dilutive funding and broader development capabilities within a 2-5 year timeframe.

What Are NHWK's Competitive Advantages?

• Proprietary gp96 platform, including ImPACT and ComPACT technologies, offering unique mechanisms for immune system modulation.
• Intellectual property surrounding its platform and pipeline candidates, providing exclusivity for its novel therapies.
• Advancing clinical pipeline with candidates like HS-110 (Phase II), HS-130 (Phase I), and PTX-35 (Phase I), representing significant R&D investment and progress.
• Specialized expertise in immuno-oncology and vaccine development, fostering innovation in complex therapeutic areas.

What Does NHWK Do?

NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm, dedicated to advancing immune therapies and vaccines with a core mission to leverage and modify the body's immune system to combat a range of illnesses, particularly various cancers and infectious diseases. The company was originally established as Heat Biologics, Inc. in 2008, and underwent a significant rebranding to NightHawk Biosciences, Inc. in May 2022, reflecting its evolving strategic focus. Headquartered in Morrisville, North Carolina, the company employs 77 individuals focused on research, development, and clinical advancement. Central to NightHawk's strategy is its proprietary gp96 platform, which serves as the technological backbone for its therapeutic development. This platform encompasses two key technologies: ImPACT and ComPACT. ImPACT is an allogeneic, or 'off-the-shelf,' cell-based system specifically designed to activate and expand T-cells, functioning as a broad immune stimulant. ComPACT, on the other hand, combines antigen-specific T-cell activation with targeted co-stimulation within a single product, aiming for more precise and potent immune responses. The company's clinical pipeline features several promising candidates, including HS-110, which has completed enrollment for its Phase II clinical trial targeting advanced non-small cell lung cancer. Additionally, HS-130 is currently undergoing a Phase I clinical trial for advanced solid tumors, and PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25, is also in Phase I development. NightHawk is also exploring DR3/TNFRSF25 as a general target for various immunotherapy applications. Beyond oncology, the company maintains a preclinical COVID-19 vaccine program, demonstrating its commitment to infectious disease prevention. A notable collaboration involves Dr. James Shapiro at the University of Alberta, focusing on the manufacturing of a surrogate mouse version of PTX-35, underscoring the company's engagement in scientific partnerships to advance its pipeline.

What Products and Services Does NHWK Offer?

• Develops immune therapies and vaccines to combat cancers and infectious diseases.
• Utilizes a proprietary gp96 platform with ImPACT and ComPACT technologies.
• ImPACT is an allogeneic (off-the-shelf) cell-based system for T-cell activation.
• ComPACT combines antigen-specific T-cell activation with targeted co-stimulation.
• Has a clinical pipeline including HS-110 for advanced non-small cell lung cancer (Phase II).
• Developing HS-130 for advanced solid tumors (Phase I).
• Developing PTX-35, a T-cell co-stimulator agonist antibody, for advanced solid tumors (Phase I).
• Explores DR3/TNFRSF25 as a general target for various immunotherapy applications.
• Maintains a preclinical COVID-19 vaccine program.

How Does NHWK Make Money?

• Primarily focused on research and development of novel biopharmaceutical products.
• Aims to generate revenue through successful commercialization of approved drugs, including sales and distribution.
• Potential for licensing agreements or strategic partnerships for its proprietary platform or pipeline assets.
• Future revenue streams would depend on regulatory approvals and market adoption of its therapeutic candidates.

What Industry Does NHWK Operate In?

NightHawk Biosciences, Inc. operates within the dynamic and highly competitive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intensive research and development, lengthy clinical trial processes, and significant regulatory hurdles. The company's focus on immune therapies and vaccines places it squarely within the rapidly expanding immuno-oncology market, which is projected to reach substantial valuations driven by increasing understanding of the immune system's role in disease and the demand for more targeted treatments. NightHawk's proprietary gp96 platform positions it to potentially differentiate its offerings from traditional therapies. The competitive landscape includes large pharmaceutical companies with established pipelines and numerous smaller biotechs vying for market share with novel approaches. Success in this industry hinges on scientific innovation, clinical efficacy, and the ability to secure intellectual property and funding.

Who Are NHWK's Key Customers?

• Ultimately, patients suffering from various cancers and infectious diseases who could benefit from advanced immune therapies.
• Healthcare providers, including oncologists and infectious disease specialists, who prescribe and administer treatments.
• Hospitals and clinics that procure and utilize biopharmaceutical products.
• Potentially other pharmaceutical companies through collaborative development or licensing agreements for its platform technology.

Company Profile

NightHawk Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Morrisville, US. The company is led by CEO Jeffrey Alan Wolf. NHWK has traded publicly since 2013.

How NightHawk Biosciences, Inc. Is Valued

NightHawk Biosciences, Inc. carries a market capitalization of $10.8M, placing it in the micro-cap category. Relative to its peer group, NHWK's quantitative score of 43/100 is below the peer average of 76/100.

Return on equity for NightHawk Biosciences, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -76.0%, showing how much profit it generates from its asset base. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching.

NightHawk Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.72 places it in the distress zone, a signal of elevated financial risk.

NHWK Financials

NHWK Latest News

No recent news available for NHWK.

NHWK Analyst Consensus

NHWK MoonshotScore

Common Questions About NHWK (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources